secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001562762-24-000250
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical Q3 net sales $625.7M (+63% YoY), raises FY24 revenue and EPS guidance
--------------------------------------------------------------------------------

- Worldwide net sales $625.7M, up 63.1% YoY, driven by NuVasive addition and higher spine/enabling tech sales.
- GAAP diluted EPS $0.38 (vs $0.01 in Q3 2023); non-GAAP diluted EPS $0.83 (vs $0.57, +45.2%).
- Non-GAAP adjusted EBITDA $193.7M, or 31.0% of net sales.
- Raised FY2024 guidance: revenue $2.49-$2.50B; non-GAAP diluted EPS $2.90-$3.00 (includes $0.09 change in treatment of IPR&D).
- Net cash from operations $203.7M; non-GAAP free cash flow $161.7M in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000156276224000250/0001562762-24-000250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000156276224000250/gmed-20241105x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-24-000250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer